Relafen and Gingival disorder - a phase IV clinical study of FDA data

Summary:

Gingival disorder is reported as a side effect among people who take Relafen (nabumetone), especially for people who are female, 50-59 old, also take Zometa, and have Anaemia.

The phase IV clinical study analyzes which people have Gingival disorder when taking Relafen. It is created by eHealthMe based on reports of 5,961 people who have side effects when taking Relafen from the FDA, and is updated regularly.

What is Relafen?

Relafen has active ingredients of nabumetone. It is often used in arthritis. eHealthMe is studying from 6,243 Relafen users. Check the latest studies of Relafen.

What is Gingival disorder?

Gingival disorder (gum disease) is found to be associated with 669 drugs and 568 conditions by eHealthMe. Check the latest studies of Gingival disorder.

On Jul, 02, 2026

5,961 people reported to have side effects when taking Relafen.
Among them, 25 people (0.42%) have Gingival disorder.

Among these 25 people:

What is the gender of people who have Gingival disorder when taking Relafen? *

female: 58.33 %
male: 41.67 %

What is the age of people who have Gingival disorder when taking Relafen? *

What are other drugs people take besides Relafen? *

What are other side effects people have besides Gingival disorder? *

Neuropathy Peripheral (surface nerve damage): 24 people, 96.00%
Injury: 24 people, 96.00%
Stress And Anxiety: 24 people, 96.00%
Anaemia (lack of blood): 24 people, 96.00%
Fever: 24 people, 96.00%
Musculoskeletal Chest Pain (pain in chest muscle or nerve or bones): 24 people, 96.00%
Hypoaesthesia (reduced sense of touch or sensation): 23 people, 92.00%
Osteonecrosis Of Jaw (death of bone of jaw): 23 people, 92.00%
Osteolysis (dissolution of bone): 20 people, 80.00%
Depression: 20 people, 80.00%

What are the existing conditions these people have? *

Musculoskeletal Pain (pain affects the bones, muscles, ligaments, tendons, and nerves): 10 people, 40.00%
Anaemia (lack of blood): 10 people, 40.00%
Multiple Myeloma (cancer of the plasma cells): 9 people, 36.00%
Osteoporosis (bones weak and more likely to break): 4 people, 16.00%
Behcet's Syndrome (involves inflammation of the blood vessels): 4 people, 16.00%
Metastases To Bone (cancer spreads to bone): 1 person, 4.00%
Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Relafen and have Gingival disorder?

- Check whether Gingival disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Relafen:

Relafen (6,243 reports)

Browse all side effects of Relafen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Gingival disorder:

Gingival disorder (669 drugs)

Browse all the conditions that are associated with Gingival disorder:

Gingival disorder (568 conditions)

Related publications that referenced our studies

Hung SC, Liao KF, Hung HC, Lin CL, Lai SW, Lin CH, "Nabumetone use and risk of acute pancreatitis in a case-control study", Pancreatology, 2016 Jun .
Hung SC, Liao KF, Hung HC, Lin CL, Lai SW, Lin CH, "Nabumetone use and risk of acute pancreatitis in a case-control study", Pancreatology, 2016 Jun .

How the study uses the data?

The study uses data from the FDA. It is based on nabumetone (the active ingredients of Relafen) and Relafen (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.